ru/ ru

ISSN: 1023-5086


ISSN: 1023-5086

Scientific and technical

Opticheskii Zhurnal

A full-text English translation of the journal is published by Optica Publishing Group under the title “Journal of Optical Technology”

Article submission Подать статью
Больше информации Back

УДК: 535-15, 615.275.4, 617.7, 617.735, 617.754.7

Alternative approach to laser methods of treating vascular pathologies of the eye

For Russian citation (Opticheskii Zhurnal):

Серебряков В.А., Папаян Г.В., Астахов Ю.С., Овнанян А.Ю. Альтернативный подход к лазерным методам лечения сосудистых патологий глаза // Оптический журнал. 2014. Т. 81. № 11. С. 15–30.


Serebryakov V.A., Papayan G.V., Astakhov Yu.S., Ovnanyan A.Yu. Alternative approach to laser methods of treating vascular pathologies of the eye [in Russian] // Opticheskii Zhurnal. 2014. V. 81. № 11. P. 15–30.

For citation (Journal of Optical Technology):

V. A. Serebryakov, G. V. Papayan, Yu. S. Astakhov, and A. Yu Ovnanyan, "Alternative approach to laser methods of treating vascular pathologies of the eye," Journal of Optical Technology. 81(11), 631-641 (2014).


This article discusses a new approach to the treatment of one of the most serious diseases of the retina—age-related degeneration of the macula, which produces persistent reduction of visual acuity. For effective and minimally traumatic treatment, it is proposed to use the combined action of medications with photodynamic therapy and thermal therapy based on the IR photosensitizer Indocyanine Green. The possibility is considered of increasing the treatment efficiency by enhancing the quantum yield of singlet oxygen and increasing the optical density of the photosensitizer by encapsulating it inside polymeric nanocarriers.


combined therapy, age-related degeneration of macula, photodynamic therapy, quantum yield of Indocyanine Green, micellar nanocarriers, neovascularization


This work was carried out with the financial support of the Ministry of Education and Science of the Russian Federation (Contract No. 14.579.21.0015).

OCIS codes: 140.3070, 170.5180, 220.4241


1. Yu. S. Astakhov and N. Yu. Dal’, “New possibilities of treating neovascular age-related macular degeneration,” Ross. Oftal’mol. Zh. No. 1, 52 (2008).
2. É. V. Boı˘ko, L. V. Zhuravleva, and S. V. Sosnovskiı˘, Age-Related Macular Degeneration (Risk Factors, Classification, Diagnosis, Prophylaxis, Treatment). Methodical Recommendations (VMA im. S. M. Kirova, MO RF, Moscow, 2009).
3 .S. A. Alpatov, E. M. Urneva, A. G. Shchuko, and V. V. Malyshev, “Evaluating the development of wet age-related macular degeneration by means of high-resolution optical coherent tomography,” Klinich. Oftal’mol. 10, No. 3, 97 (2009).
4. L. P. Iu and A. K. Kwok, “An update of treatment options for neovascular age-related macular degeneration,” Hong Kong Med. J. 13, 460 (2007).
5. É.V. Boı˘ko, S. V. Sosnovskiı˘, R. D. Berezin, P. A. Kacherovich, and D. A. Tavtilo, “Intravitreal injection: theory and practice,” Oftal’mol. Vedomosti 3, No. 2, 28 (2010).
6. K. Atmani, M. Voigt, V. Le Tien, G. Querques, G. Coscas, G. Soubrane, and E. H. Souied, “Ranibizumab for retinal angiomatous proliferation in age-related macular degeneration,” Eye 24, 1193 (2010).
7. P. Hagan, “The beam of energy that could save you from blindness,” The Daily Mail, April 2011.
8. A. J. Witkin, L. N. Vuong, V. J. Srinivasan, I. Gorczynska, E. Reichel, C. R. Baumal, A. H. Rogers, J. S. Schuman, J. G. Fujimoto, and J. S. Duker, “High-speed ultrahigh-resolution OCT before and after ranibizumab for AMD,” Ophthalmology 116, 956 (2009).
9. N. Lois, V. Mcbain, E. Abdelkader, N. W. Scott, and R. Kumari, “Retinal pigment epithelial atrophy in patients with exudative age-related macular degeneration undergoing anti-vascular endothelial growth factor therapy,” Retina 33, No. 1, 13 (2013).
10. A. Koh, “Verteporfin photodynamic therapy for AMD in the anti-VEGF era,” Retina Today, April 2010.
11. “The use of Lucentis and Avastin in the treatment of age-related macular degeneration,” Omnipharm. March 16, 2009.
12. S. Piermarocchi, M. Sartore, L. G. Giudice, V. Maritan, E. Midena, and T. Segato, “Combination of photodynamic therapy and intraocular triamcinolone for exudative age-related macular degeneration and long-term chorioretinal macular atrophy,” Arch. Ophthalmol. 126, 1367 (2008).
13. A. Brown, W. Hodge, S. Kymes, A. Cruess, G. Blackhouse, R. Hopkins, L. McGahan, S. Sharma, I. Pan, J. Blair, D. Vollman, and A. Morrison, “Management of neovascular age-related macular degeneration: systematic drug class review and economic evaluation,” Technology Report No. 110, (CADTH, Ottawa, April, 2008).
14. G. M. Comer, T. A. Ciulla, M. H. Criswell, and M. Tolentino, “Current and future treatment options for nonexudative and exudative age-related macular degeneration,” Drugs Aging 21, 967 (2004).
15. B. T. Smith, “Treatment of neovascular AMD: past, present and future directions,” Curr. Opin. Ophthalmol. No. 18, 240 (2007).
16. C. Campa, C. Costagliola, C. Incorvaia, C. Sheridan, F. Semeraro, K. De Nadai, A. Sebastiani, and F. Parmeggiani, “Inflammatory mediators and angiogenic factors in choroidal neovascularization: pathogenetic interactions and therapeutic implications,” Mediat. Inflamm. 2010, Article ID 546826 (2010).
17. “Bayer and Regeneron say VEGF Trap-Eye improves treatment of wet AMD,” Genetic Engineering & Biotechnology News, Nov. 22, 2010.
18. J. Ambati, “Major breakthrough in macular degeneration,” University of Kentucky, June 2009.
19. J. Ambati, “A new target for neovascular AMD,” Retina Today, June 2010.
20. Å. Andrén-Sandberg, Photodynamic Therapy: A Review With Special Reference to Treatment of Solid Organs (Karolinska University Hospital, Stockholm, 2007).
21. W. Foulds, C. Kaur, C. D. Luu, and W. K. Kek, “A role for photoreceptors in retinal oedema and angiogenesis: an additional explanation for laser treatment?” Eye No. 5, 918 (2009).
22. F. E. Shadrichev and E. E. Krasnoshchekova, “PASCAL—pattern-scanning laser apparatus,” Oftal’molog. Vedom. 3, No. 2, 48 (2010).
23. Y. M. Paulus, D. Palanker, and M. S. Blumenkranz, “Short-pulse laser treatment: redefining retinal therapy,” Retinal Physician, Jan. 2010.
24. B. Fuisting and G. Richard, “Transpupillary thermotherapy (TTT)—review of the clinical indication spectrum,” Med. Laser Appl. No. 25, 214 (2010).
25. Y. M. Paulus, C. Sramek, M. S. Blumenkranz, and D. Palanker, “New horizons in retinal laser treatment sublethal retinal laser therapy,” Retinal Physician, March 2011.
26. S. Miura, H. Nishiwaki, Y. Ieki, Y. Hirata, Y. Honda, Y. Sugino, and Y. Okazaki, “Chorioretinal temperature monitoring during transpupillar thermotherapy for choroidal neovascularisation,” Br. J. Ophthalmol. No. 89, 475 (2005).
27. V. A. Serebryakov, É V. Boı˘ko, and A. V. Yan, “Real-time optoacoustic monitoring of the temperature of the retina during laser therapy,” Opt. Zh. 81, No. 6, 14 (2014) [J. Opt. Technol. 81, 312 (2014)].
28. N. M. Bressler and S. B. Bressler, “Photodynamic therapy with verteporfin (Visudyne): impact on ophthalmology and visual sciences,” Invest. Ophthalmol. Vis. Sci. 41, 624 (2000).
29. “Visudyne (Verteporfin) photodynamic therapy,” Clinical Policy Bulletin No. 0594 (Aetna Inc., Hartford, Conn., 2009).
30. L. Wu and T. Evans, “Neovascularization, choroidal: treatment & medication,” eMedicine Ophthalmology, Feb. 23, 2010.
31. A. F. Mironov, “Photodynamic cancer therapy—a new and effective method of diagnosis and treatment of malignant tumors,” Soros. Obraz. Zh. No. 8, 32 (1996).
32. H. Van den Bergh and J.-P. Ballini, “Principles of PDT,” in PDT of Ocular Diseases, E. S. Gragoudas, J. W. Miller, and L. Zografos, eds. (University College London Hospitals, London, 2004), pp. 11–42.
33. S. Mennel, “Ocular photodynamic therapy—standard applications and new indications (Part 2),” Ophthalmologica No. 5, 282 (2007).
34. A. Pirracchio, P. Michieletto, F. Bandello, and P. Lanzetta, “Transpupillary thermotherapy: a developing approach in the treatment of occult subfoveal choroidal membranes during age-related macular degeneration,” J. Bombay Ophthal. Assoc. No. 1, 135 (2011).
35. M. V. Gatsu, “A comprehensive system of functionally conservative lasersurgery technologies for treating vascular and dystrophic illnesses of the retina,” Doctoral dissertation (SPb filial FGU MNTK Mikrokhirurgiya glaza, St. Petersburg, 2008).
36. C. M. Eandi, M. D. Ober, K. B. Freund, J. S. Slakter, and L. A. Yannuzzi, “Selective PDT for neovascular AMD with polypoidal choroidal neovascularization,” Retina 27, 825 (2007).
37. M. R. Detty, S. L. Gibson, and S. J. Wagner, “Current clinical and preclinical photosensitizers for use in PDT,” J. Med. Chem. 47, 3897 (2004).
38. A. V. Reshetnikov, “Photosensitizers in modern clinical practice (Review),” in Materials of the Scientific–Practical Conference of Otorhinolaryngolists of the Central Federal District of the Russian Federation, Laser Technologies in Otorhinolaryngology, Tula, Russia, Sept. 2007.
39. Y. Huang, G. Xu, Y. Peng, S. Chen, and Y. Wu, “Zinc phthalocyanine tetrasulfonate (ZnPcS4 ): a new photosensitizer for photodynamic therapy in choroidal neovascularization,” J. Ocul. Pharmacol. Therap. 23, 377 (2007).

40. Y. Huang, G. Xu, Y. Peng, H. Lin, X. Zheng, and M. Xie, “Photodynamic effects of ZnPcS4-BSA in human retinal pigment epithelium cells,” J. Ocul. Pharmacol. Therap. 25, 231 (2009).
41. M. Berdugo, R. A. Bejjani, F. Valamanesh, M. Savoldelli, J. Jeanny, D. Blanc, H. Ficheux, A. Scherz, Y. Salomon, D. BenEzra, and F. Behar-Cohen, “Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes,” Invest. Ophthalmol. Vis. Sci. 49, 1633 (2008).
42. J. A. Cardillo, R. Jorge, R. A. Costa, S. M. T. Nunes, O. Lavinsky, B. O. Kuppermann, A. C. Tedesco, and M. E. Farah, “Experimental selective choriocapillaris photothrombosis using a modified ICG formulation,” Br. J. Ophthalmol. No. 92, 276 (2008).
43. U. Schmidt-Erfurth and T. Hasan, “Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration,” Surv. Ophthalmol. 45, No. 3, 195 (2000).
44. T. Zhimin, “The mechanisms of cellular sensitivity to photofrin-mediated PDT,” Dissertation (McMaster University, Hamilton, Ontario, 2001).
45. S. Mennel, “Ocular photodynamic therapy—standard applications and new indications (Part 2),” Ophthalmologica 221, 282 (2007).
46. T. A. Fuller, F. E. O’Donnell, and C. Santos, “Thermally labile liposomes for treatment of blinding retinal disease,” Drug Deliv. Technol. 3, No. 4 (2003).
47. M. E. Farah, J. A. Cardillo, A. C. Luzardo, D. Calucci, G. A. Williams, and R. A. Costa, “Indocyanine Green mediated photothrombosis for the management of predominantly classic choroidal neovascularisation caused by age-related macular degeneration,” Br. J. Ophthalmol. No. 88, 1055 (2004).
48. N. V. Pasechnikova, Yu. Gut, and I. Gut, “Diagnostics of the pathology of the fundus of the eye,” Oftal’molog. Zh. No. 2, 63 (2008).
49. E. Engel, R. Schraml, T. Maisch, K. Kobuch, B. Konig, R. Szeimies, J. Hillenkamp, W. Baumler, and R. Vasold, “Light-induced decomposition of Indocyanine Green,” Invest. Ophthalmol. Vis. Sci. 49, 1777 (2008).
50. J. D. Wolfe, “Vessel formation and feeder vessel treatment in choroidal neovascularization,” Master’s thesis (Medical College of Ohio, 2004).
51. A.-K. Kirchherr, A. Briel, and K. Mader, “Stabilization of indocyanine green by encapsulation within micellar systems,” Mol. Pharmacol. 6, 480 (2009).
52. Ž. Lukšienė, “Photodynamic therapy: mechanism of action and ways to improve the efficiency of treatment,” Medicina 39, 1137 (2003).
53. M. Heger, I. Salles, R. Bezemer, M. A. Cloos, S. R. Mordon, S. Bégu, H. Deckmyn, and J. F. Beek, “Laser-induced primary and secondary hemostasis dynamics and mechanisms in relation to selective photothermolysis of port wine stains,” J. Dermatol. Sci. 63, 139 (2011).
54. P. Liu, C. Yue, B. Shi, G. Gao, M. Li, B. Wang, Y. Ma, and L. Cai, “Dextran-based sensitive theranostic nanoparticles for near-infrared imaging and photothermal therapy in vitro,” Chem. Commun. No. 49, 6143 (2013).
55. Z. Wan, H. Mao, M. Guo, Y. Li, A. Zhu, H. Yang, H. He, J. Shen, L. Zhou, Z. Jiang, C. Ge, X. Chen, X. Yang, G. Liu, and H. Chen, “Highly efficient hierarchical micelles integrating photothermal therapy and singlet oxygen-synergized chemotherapy for cancer eradication,” Theranostics 4, 399 (2014).
56. A. J. Augustin, S. Puls, and I. Offermann, “Triple therapy for choroidal neovascularization due to age-related macular degeneration: Verteporfin PDT, bevacizumab and dexamethasone,” Retina 27, 133 (2007).
57. N. V. Neroeva, “Modern methods of treating the neovascular form of VM,” Dissertation (Medical Scientific Research Institute of Diseases of the Eye, Moscow, 2010).
58. U. Stolba, I. Krebs, P. D. Lamar, T. Aggermann, D. Gruber, and S. Binder, “Long-term results after transpupillar thermotherapy in eyes with occult choroidal neovascularisation associated with age-related macular degeneration: a prospective trial,” Br. J. Ophthalmol. 90, 158 (2006).
59. G. Peyman, M. Tsipursky, P. Gohel, and M. Conway, “Regression of peripapillary choroid neovascularization after oscillatory transpupillar thermotherapy and anti-VEGF pharmacotherapy,” Eur. J. Ophthalmol. 21, 162 (2011).
60. J. W. Miller, “Photodynamic therapy for choroidal neovascularization,” Graefe’s Arch. Clin. Exp. Ophthalmol. No. 241, 258 (2003).
61. M. Piechocki, “Laser-dye hybrid shows potential for various CNV forms,” Ocular Surgery News, U.S. Edition, Dec. 2003.
62. J. F. Arevalo, R. A. Garcia, and A. J. Mendoza, “Indocyanine Green-mediated photothrombosis with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization in age-related macular degeneration,” Graefe’s Arch. Clin. Exp. Ophthalmol. No. 243, 1180 (2005).
63. A. J. Augustin, “Combination therapies in Europe for AMD treatment: Part 2,” Macular Degeneration Treatment, June 21, 2011.
64. U. Schmidt-Erfurth, C. Kiss, and S. Sacu, “The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies,” Prog. Retin. Eye Res. No. 28, 145 (2009).
65. P. Fernández-Robredo, A. Sancho, S. Johnen, S. Recalde, N. Gama, G. Thumann, J. Groll, and A. García-Layana, “Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering,” J. Ophthalmol. 2014, Article ID 510285, (2014).